Breathing in a cancer fighter: inhaled IL-2 trial targets lung tumors

NCT ID NCT01590069

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an inhaled form of interleukin-2 (IL-2), a protein that boosts the immune system, in people whose cancer has spread to the lungs. The goal is to find the best dose and see if it can shrink lung tumors. About 70 adults with cancers like melanoma, sarcoma, or kidney cancer are taking part. The treatment is breathed in through a nebulizer, and researchers monitor side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aerosolized interleukin-2 (aldesleukin)
What this could lead to
If it works, this could offer a new way to treat lung metastases by boosting the immune system directly in the lungs, potentially controlling tumor growth.
What could go wrong
This is an early phase trial with a small number of participants, so the benefits are uncertain. Side effects from immune stimulation may occur, and it may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.